Sentences with phrase «outcomes at trial»

Attorney bargaining has traditionally taken place in the shadow of trial, as litigants alter their pretrial behavior — including their willingness to negotiate a settlement — based on perceptions of likely outcomes at trial and anticipated litigation costs.

The majority of personal injury lawyers would only take a portion of your money (a contingency fee) if you receive a positive outcome at trial.

If not, the attorney will do whatever is legally possible to ensure that you obtain the best outcome at trial.

[80] To demonstrate an impairment of the right to make full answer and defence as a result of a default or delay in disclosure, an appellant must establish a reasonable possibility that the delayed or failed disclosure affected the outcome at trial or the overall fairness of the trial process: Dixon at para. 34; Stinchcombe at p. 348; R. v. C. (M. H.), 1991 CanLII 94 (S.C.C.), [1991] 1 S.C.R. 763, at p. 776.

Family litigation is not always a swift process and it is not unusual for the Court to make temporary orders pending the final outcome at trial.

Passionate and logical arguments help us to get you the best possible outcome at trial.

Whether acting for plaintiffs, defendants, or third parties, our lawyers maintain their focus on achieving the best possible outcome for our clients through settlement, alternative dispute resolution, or a successful outcome at trial.

In relation to the alleged failures to carry on cases with proper care thus losing NIG the opportunity of securing a successful outcome at trial or by favourable settlement, Flaux J held that actual damage was suffered when as a consequence of a breach there was a material diminution in the prospects of an accepted claim's success.

Not exact matches

Participants in United Therapeutics» clinical trials now have their genomes sequenced and researchers at the company plan to correlate patient outcomes with that genomic sequence data.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

We can never be 100 % confident in the outcome of a trial, perhaps, but at least we know each side had its bulldog.

For instance, we were once in a proceeding in which the judge made a ruling on evidence presented at trial by opposing counsel that was going to fundamentally change the outcome of the case.

The rules are targeted at comments likely to affect the outcome of a trial or the impartiality of jurors.

can we at least wait to see the outcome of the trial?

No matter the outcome of Euro 2012, or of his trial, the court of public opinion — which has little respect for matters sub judice at the best of times — handed down its verdict long ago.

The largest randomized trial of a comprehensive early intervention program for low - birth - weight, premature infants (birth to age three), the Infant Health and Development Program, included a home visiting component along with an educational centre - based program.7 At age three, intervention group children had significantly better cognitive and behavioural outcomes and improved parent - child interactions.

The program of prenatal and infancy home visiting by nurses has produced consistent effects on clinically significant outcomes in three separate trials with different populations living in different contexts and at different points in U.S. social and economic history.

No trials reported on longer - term outcomes: any breastfeeding at three months; prolonged perineal pain; pain during sexual intercourse; urinary incontinence; faecal incontinence; and prolonged backache.

A randomised controlled trial of caseload midwifery for women at low risk of medical complications (COSMOS): Maternal and infant outcomes

Not all secondary outcomes listed in protocol were reported, but these were not outcomes of interest in this review so we marked this trial as being at low risk of bias.

Declan Devane is a co-author in one of the included trials in this review (Begley 2011) Jane Sandall was and is principal investigator for two studies evaluating models of midwife - led continuity of care (Sandall 2001), and co-investigator on the «Birthplace in England Research Programme», an integrated programme of research designed to compare outcomes of births for women planned at home, in different types of midwifery units, and in hospital units with obstetric services.

As this may be a consequence of infrequent feeding bouts, particularly at night, we hypothesised that those infants sleeping in close proximity to their mothers on the postnatal ward in the trial described above (bed or crib) would have better long - term breastfeeding outcomes than infants randomly allocated to the stand - alone cot.

The Effect of Timing of Cord Clamping on Neonatal Venous Hematocrit Values and Clinical Outcome at Term: A Randomized, Controlled Trial José M. Ceriani Cernadas, Guillermo Carroli, Liliana Pellegrini, Lucas Otaño, Marina Ferreira, Carolina Ricci, Ofelia Casas, Daniel Giordano and Jaime Lardizábal Pediatrics 2006; 117; 779 - 786; originally published online Mar 27, 2006; DOI: 10.1542 / peds.2005 - 1156 Download file in 380 kb - 10 pages The online version of this article, along with updated information and services, is located on the World Wide Web at: http://www.pediatrics.org/cgi/content/full/117/4/e779 Background: The umbilical cord is usually clamped immediately after birth.

A randomised controlled trial of caseload midwifery for women at low risk of medical complications (COSMOS)- primary and secondary outcomes

Citizens have been disappointed at the outcomes of former regime members» trials, and the lack of vetting, whether in Egypt's police apparatus, prison system, or official media.

The outcome of the Liang case is imperiled by an unusual and unexpected question: Did one of the jurors, a retired carpenter, hide his father's criminal past in order to be a panelist at the trial?

After the positive results from a random drug test, she was pulled from her security post at Gracie Mansion and remains on paid desk duty in Queens pending the outcome of the trial.

«We believe these studies and clinical trials that combine immunotherapy with chemotherapy are advancing efforts toward better clinical care and more positive outcomes for our patients at CTCA,» said Dr. Vivek Khemka, Medical Oncologist, CTCA at Western and the WCLC study abstract's principal investigator and senior author.

A late - breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump function).

Researchers at Dana - Farber / Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only.

Both adverse outcomes need to be studied further, according to Legro, who led a team that hosted the Chinese collaborators at Penn State College of Medicine for five weeks as the group wrote the protocol for the multi-center trial and participated in regular steering committee meetings overseeing the trial.

And even when it is an option, researchers aren't always sure how to interpret data from trials that changed protocol midstream, says James Hoffman, medication outcomes and safety officer at the St. Jude Children's Research Hospital in Memphis, Tennessee.

Jennifer A. Woyach, M.D., of Ohio State University, Columbus, and coauthors described the characteristics of patients who discontinued ibrutinib therapy and their outcomes in a group of 308 patients participating in four trials at a single institution.

Researchers, Dr Abi Rose and Dr Andy Jones, from the University's Addiction Research Team conducted a meta - analysis on all 12 clinical trials comparing baclofen with placebo on at least one of the described drinking outcomes, craving, anxiety, or depression.

«For the first time, we can predict the outcomes of modifying multiple genes involved in lignin biosynthesis, rather than working with a single gene at a time through trial and error, which is a tedious and time - consuming process,» says Jack Wang, assistant professor in NC State's College of Natural Resources and lead author of a paper about the research in Nature Communications.

«Since several BACE1 inhibitors are currently being evaluated in clinical phase 3 trials for the treatment of Alzheimer's disease, the identification of potential side effects will be of great importance to ensure a positive clinical outcome,» said Dr. Jochen Herms, a Professor of translational brain research at Ludwig - Maximilians - University Munich.

A phase 2 trial showed a reduction in the combined outcome of death or myocardial infarction (heart attack) in patients treated with otamixaban compared with unfractionated heparin (UFH) plus eptifibatide (an antiplatelet drug) and showed similar bleeding rates with otamixaban at midrange doses.

«We had 100 percent completion of all outcome measures from parents and teachers, indicating that there is an ease to this method of testing that engages parents at a higher rate than traditional trials.»

The results of the Endovascular Therapy Following Imaging Evaluation for the Ischemic Stroke (DEFUSE 3) trial, presented at the International Stroke Conference 2018 in Los Angeles and published on Jan. 24 in the New England Journal of Medicine, demonstrated that physically removing brain clots up to 16 hours after symptom onset in selected patients led to improved outcomes compared to standard medical therapy.

Yale enrolled the largest number of participants at any one site (84 of 790) for these double - blind, placebo - controlled trials that investigated the efficacy of testosterone gel for multiple outcomes, including sexual function, physical function, and vitality.

«Previous studies suggest that reducing heart fat is feasible through weight loss or weight management, but these studies only looked at small numbers of people and there have been no clinical trials linking cardiovascular outcomes with heart fat changes due to weight management interventions.

«The recent niacin clinical trials offer important new evidence that raising «good» cholesterol (HDL) levels on top of statin therapy does not have the positive outcome that had been hoped for,» said Neil Stone, M.D., the Robert Bonow MD Professor in Cardiology at Feinberg and a cardiologist at Northwestern Memorial Hospital.

A Tufts spokesperson said the three researchers at that university involved in the trial would not comment on the Chinese report; Tufts is currently conducting its own review and is declining to comment as well pending its outcome.

In this randomized controlled PARTNER 2A trial, outcomes using the SAPIEN XT valve were compared with open - heart surgery valve replacement among 2,032 intermediate - risk patients treated between December 2011 and November 2013 at 57 sites, all but two in the U.S. Patients were randomly assigned; 1,011 to TAVR and 1,021 to surgery.

These highly anticipated study findings, Two - Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation, were presented today by Robert Michler, M.D. at the American College of Cardiology Scientific Session 2016 and published simultaneously in the New England Journal of Medicine by the Cardiothoracic Surgical Trials Network (CTSN).

This study was presented at the Featured Clinical Research Session I: Two - year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation: A Randomized Clinical Trial from The Cardiothoracic Surgical Trials Network The Moderate Ischemic Mitral Regurgitation trial was supported by a cooperative agreement (U01 HL088942) funded by the National Heart Lung and Blood Institute, the National Institutes of Neurological Disorders and Stroke of the National Institutes of Health (NIH), Bethesda, MD, and the Canadian Institutes of Health ReseTrial from The Cardiothoracic Surgical Trials Network The Moderate Ischemic Mitral Regurgitation trial was supported by a cooperative agreement (U01 HL088942) funded by the National Heart Lung and Blood Institute, the National Institutes of Neurological Disorders and Stroke of the National Institutes of Health (NIH), Bethesda, MD, and the Canadian Institutes of Health Resetrial was supported by a cooperative agreement (U01 HL088942) funded by the National Heart Lung and Blood Institute, the National Institutes of Neurological Disorders and Stroke of the National Institutes of Health (NIH), Bethesda, MD, and the Canadian Institutes of Health Research.

In order to show that the use of this system improves patient outcomes, a clinical trial at the Montreal Neurological Institute and Hospital will be launched for patients with newly diagnosed and recurrent glioblastoma.

Their outcomes were compared with patients receiving standard care at the same clinics for the 3 months prior to the trial's start.

The main outcome in trial 2 was the frequency of women with malaria parasites in their blood (parasitemia) at delivery.

The STAR trial was conducted under controlled conditions, while the Penn study takes the next step by looking at outcomes in post-approval clinical use of the device.